You can view the research column published every month by SMC Laboratories.
2025.02.02
Combination study with our proprietary NASH-HCC model
We would like to introduce the combination study using NASH model mice. Combination study in NASH These…
READ MORE
2025.02.02
SSc-ILD mouse model for simultaneous development of skin and lung fibrosis
We would like to introduce our SSc-ILD model – an improvement on our existing systemic scleroderma model – whi…
READ MORE
2025.02.02
Acute Lung Injury mouse model shows similar symptoms to COVID-19 patients
We would like to introduce the Liposaccharide-induced Acute Lung Injury model (LPS model) – an ARDS model that…
READ MORE
2025.02.02
Liver Orthotopic Xenograft mouse model
We would like to introduce the Liver Orthotopic Xenograft mouse model – a cancer model that also allows the ev…
READ MORE
2025.02.02
Performance of FXR agonist pharmacology studies using our NASH model
We would like to share with you about our experience evaluating farnesoid X receptor (FXR) agonists in the wor…
READ MORE
2025.02.02
Introduction of our original chronic liver disease model mouse
We would like to introduce today the world’s first mouse model that induces liver cancer from nonalcohol…
READ MORE
2025.02.02
Growing demand for NASH therapeutics due to COVID-19 severity risk
It has been reported that various metabolic diseases are a factor in COVID-19 severity, and an increased risk …
READ MORE
2025.02.02
COVID-19 and Pulmonary fibrosis
We would like to introduce an update regarding the relationship between pulmonary fibrosis and COVID-19, which…
READ MORE
2025.02.02
Galectin-3 in IPF model
We would like to introduce Galectin-3, a potential therapeutic target molecule in Idiopathic Pulmonary Fibrosi…
READ MORE
2025.02.02
Versatility of our proprietary STAM mice
We would like to introduce the versatility of our proprietary NASH-HCC model (“STAM™ mice”). We have pr…
READ MORE
